tbuckley/cabot-search huggingface dataset:
OP0159 GENETICALLY DETERMINED CAUSAL RELATIONSHIP BETWEEN GOUT AND CARDIOVASCULAR DISEASE
Authors: X. Y. Yin, R. L. Zhang, H. Y. Zheng, Y. Q. Bai, Q. Yu, P. F. He, X. LI, S. X. Zhang
Journal: Annals of the Rheumatic Diseases (2023)

Background Gout is a common inflammatory arthritis caused by monosodium urate deposits around the joints[1]. The risk of cardiovascular events, including death, is substantially higher in people with gout than in those without gout[2]. Although epidemiological studies have reported a positive correlation between circulating urate levels and cardiac metabolic diseases, the causal relationship between gout and cardiovascular diseases(CVD) is still uncertain[3]. Objectives This study aimed to explore the causal relationship between gout and CVD from the genetic level. We examined the potential effects of gout on coronary heart disease(CHD), coronary artery disease(CAD), atrial fibrillation(AF), myocardial infarction(MI), pulmonary embolism(PE), any stroke, ischemic stroke and its subtypes [cardioembolic(CES), small-vessel(SVS), extensive artery atherosclerosis(LAS)]. Methods We obtained genetic information related to gout from the Global Urate Genetics Consortium (GUGC), including 2115 cases and 67259 healthy controls with 5057528 single nucleotide polymorphisms(SNPs). SNPs significantly associated with CVD were obtained from large genome-wide association(GWAS) meta-analyses and the UK Biobank as instrumental variables(IVs) for Mendelian randomization(MR). The inverse variance weighting (IVW), MR Egger, and weighted median were used to estimate the effect size. MR-PRESSO was used to detect and eliminate SNPs that may bring significant pleiotropy. Results MR results supported that gout had significant causal effects in CHD, CAD, and MI. There was a significant positive correlation between the genetic responsibility of gout and the risk of CVD(CHD: OR=1.031, 95%CI:1.007-1.057, P=0.012; CAD: OR=1.031, 95%CI:1.007-1.057, P=0.012; MI: OR=1.037, 95%CI: 1.037-1.009, P=0.009). In reverse MR, we only observed that any stroke would increase the risk of gout(OR=1.265, 95%CI: 1.010-1.585, p=0.041). No pleiotropy was detected in the sensitivity analysis(all p&gt;0.05). Conclusion The responsibility of gout had a significant causal relationship with CHD, CAD, and MI, suggesting adequate management of gout could reduce the risk of CVD. References [1] Lai, B. et al. Assessing the causal relationships between gout and hypertension: a bidirectional Mendelian randomisation study with coarsened exposures. Arthritis Res Ther 24, 243, doi:10.1186/s13075-022-02933-4 (2022). [2] White, W. B. et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med 378, 1200-1210, doi:10.1056/NEJMoa1710895 (2018). [3] Keenan, T. et al. Causal Assessment of Serum Urate Levels in Cardiometabolic Diseases Through a Mendelian Randomization Study. J Am Coll Cardiol 67, 407-416, doi:10.1016/j.jacc.2015.10.086 (2016). Acknowledgements: NIL. Disclosure of Interests None Declared.
POS0062-PARE GREAT SUCCESS FOR THE GERMAN PATIENT RESEARCH PARTNERS (PRPS): FROM THE CALL TO TENDER TO WINNING THE AWARD
Authors: C. Elling-Audersch
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> The Deutsche Rheuma-Liga is a patient organisation with about 270 000 members. We have a long history of an established PRP network. We enjoy an excellent cooperation with our professional PRP-facilitator from the steering committee of our organisation. Our patient organisation provides tools, the PRP reference-cards and a helpful brochure, and takes care of the continuing education of the PRPs. <h3>Objectives</h3> In 2022, the Deutsche Rheumastiftung (DRS; German Rheumatism Foundation) for the first time launched the call for the "Projektpreis". Four prizes were awarded with 10.000 € per prize; and at least one of them had to be a participatory research project. This was the starting point for the German PRP network. The immediate aim was to win at least one of the awards. The overarching aim was to realise, for the first time in the field of German rheumatology, a research project initiated by PRPs. <h3>Methods</h3> In order to forward the call and set out the details of the applications, the first meeting was organised by our research facilitator. We discussed various ideas and evaluated whether the objectives can be achieved or not. The subsequent meetings were organised by the PRPs themselves. We improved the initial ideas and searched for supporting researchers, in order to substantiate the planned research projects and write the applications. <h3>Results</h3> Not all ideas from our PRPs were submitted, because of time limitations and difficulties in finding an adequate researcher. In the end, three participatory research projects from German PRPs applied for the "Projektpreis". The topics of the applications were a) money for disseminating the outcomes of a participatory research project addressing fatigue in Lupus patients, b) initiation of a participatory research project investigating how patients search, find and use web-based disease information in everyday life and c) initiation of a participatory research project investigating biomarkers for fibromyalgia. The total number of applications submitted to the DRS was 14. Finally, two participatory research projects from German PRPs won two of the four prizes. The award ceremony took place during the scientific congress of the German Society for Rheumatology in Berlin. <h3>Conclusion</h3> It was a great honour for the German PRPs receiving the awards for applications based on their own initial ideas. For the Deutsche Rheuma-Liga this was a great success in terms of supporting participatory research. This example shall encourage other patient organisation to be confident in finding and creating their own participation-research project. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
POS0200-PARE HOW USER INVOLVEMENT INCREASED THE QUALITY OF PROS
Authors: C. Ziegler
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> In the DANBIO Registry patients with inflammatory arthritis have entered PROs for more than 20 years. In 2016 a group of patients suggested that their experiences and opinions about entering PROs should be taken into account, as the they found room for improvement. In 2018 a qualitative research study confirmed knowledge gaps in the use and purpose of DANBIO – gaps among patients, front personal and health care providers. In 2022 new results could be implemented. <h3>Objectives</h3> After the research study three different goals were set up: [1]To increase knowledge of the DANBIO Registry being used for three different purposes. [2]To make patients aware that they can enter PROs in different ways. [3]To assure better quality of PROs by enhancing patient's adherence. <h3>Methods</h3> An interdisciplinary user group was established. The group consisted of patients with different types of inflammatory arhtritis, rheumatologists, nurses etc. The group decided to produce different materials for different platforms. The group produced the materials themselves in a cooperation with room for everyone's professional qualifications. The patients could offer patient's experiences as well as being persons with competences from education and worklife. <h3>Results</h3> Three user guides about the use of DANBIO were produced for three target groups. A group of patients scripted, filmed and produced a 5 minutes video providing the patients with relevant knowledge of PROs in DANBIO. The video was filmed at four different rheumatological departments and in patient's private homes. The video wil be shown in the waiting rooms of the hospitals and it can be seen on the Internet. <h3>Conclusion</h3> The work of the user group created a joint understanding and a multi pronged perspective on what "good quality" means in rheumatological care. By clarifying how the same data was presented and used differently various solutions were created to meet the need for more knowledge from staff, increase patient's confidence in entering PROs and increase knowledge of the DANBIO registry in general. The video is provided with English subtitles and can be shown if this abstract is chosen for presentation. <h3>Reference</h3> [1]www.danbio.dk - www.gigtforeningen.dk <h3>Acknowledgements</h3> DANBIO. <h3>Disclosure of Interests</h3> None Declared.
POS0259 DO CHRONIC PAIN IN MULTIPLE SITES AND WIDESPREAD PAIN INCREASE RISK OF INCIDENT DEMENTIA?
Authors: J. Tian, G. Jones, X. Lin, Y. Zhou, A. King, J. Vickers, F. Pan
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Chronic musculoskeletal pain has been linked to dementia; however, chronic pain typically occurs in multiple sites, and no study has investigated the associations between number of chronic pain sites and risk of all-cause dementia and its subtypes. <h3>Objectives</h3> To investigate whether greater number of chronic pain sites is associated with a higher risk of dementia and its subtypes. <h3>Methods</h3> Participants (N=356,383) in the UK Biobank who were dementia-free at baseline were included. Pain in the hip, knee, back and neck/shoulder, or 'all over the body' and its duration were assessed. Participants were categorized into six groups: no chronic pain, and chronic pain in 1, 2, 3 and 4-sites and 'all over the body' (widespread pain). All-cause dementia and its subtypes were ascertained using hospital inpatient and death registry records. Cox regression was used to investigate the associations between number of chronic pain sites and incidence of all-cause dementia and its subtypes. <h3>Results</h3> Over a median follow-up of 13 years (interquartile range: 12.6–14.0), 4,959 participants developed dementia. After adjustment for sociodemographic, body mass index, lifestyle, comorbidities, pain medications, psychological problems and sleep factors, greater number of chronic pain sites was associated with an increased risk of incident all-cause dementia (Hazard ratio [HR]=1.08 per 1-site increase, 95%CI 1.06–1.11) and Alzheimer's disease (HR=1.09 per 1-site increase, 95%CI 1.04–1.13) in a dose-response manner, but not vascular and frontotemporal dementia. Relative to participants without chronic pain, participants having chronic pain in 2-, 3-, 4-sites and widespread pain had a higher risk of incident all-cause dementia after adjusting for confounding factors (2-sites: HR=1.18, 95%CI 1.08–1.29; 3-sites: HR=1.22, 95%CI 1.08–1.38; 4-sites: HR=1.42, 95%CI 1.19–1.70; widespread pain: HR=1.52, 95%CI 1.26–1.82). Similar results were observed for Alzheimer's disease. <h3>Conclusion</h3> Greater number of chronic pain sites was associated with an increased risk of incident all-cause dementia and Alzheimer's disease, suggesting that chronic pain in multiple sites may contribute to individuals' dementia risk and is an underestimated risk factor for dementia. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
POS0312 A REAL-LIFE COMPARATIVE STUDY OF JAK INHIBITORS AND TNF INHIBITORS IN RHEUMATOID ARTHRITIS WITH DRUG DISPENSING DATA FROM RETAIL PHARMACIES IN FRANCE
Authors: J. Sambourg, A. Gouverneur, I. Bardoulat, T. Schaeverbeke, M. E. Truchetet, M. Maravic
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> JAK inhibitors (JAKi) are recommended in the treatment of rheumatoid arthritis (RA). Concerns about real-word utilization and safety are still pending [1]. <h3>Objectives</h3> To compare 24-month persistence and safety signals of JAKi and TNF inhibitors (TNFi) in RA patients. <h3>Methods</h3> We constituted two cohorts of new users of JAKi or TNFi in Longitudinal Prescription database (LRx). The first dispensing of JAKi or TNFi constituted the index date and patients were followed up to 24 months. Persistence was time from index date to first discontinuation defined as more than 90 days without treatment of interest. Safety signals as herpes, bacterial and fungal infections, dyslipidemia, cardiovascular and thromboembolic events were approximated by dispensing of specific treatments. Cox models were used to compare outcomes between the two cohorts with Inverse Probability Treatment Weighting (IPTW) based on propensity score. <h3>Results</h3> JAKi initiators (n=2,216) were older (60 vs 56 years) and presented more cardiovascular comorbidities (43% vs 34%) than TNFi initiators (n=6,152). Persistence at 24 months was 40% [38-43] for JAKi vs 42% [40-43] for TNFi (weighted HR 1.03, 95% CI 0.96-1.11). More prescriptions of lipid-lowering drugs were observed in JAKi initiators (weighted HR 1.72, 95% CI 1.38-2.13), as well as prescriptions of antiherpetics (weighted HR 1.60, 95% CI 1.33-1.92) (figure 1). No difference was found for other events of interest. <h3>Conclusion</h3> In LRx database, JAKi and TNFi had similar 24-month persistence. JAKi initiators presented excess risk for dyslipidemia and herpes infections in comparison with TNFi initiators, while no difference was found for other safety signals, especially for cardiovascular events. <h3>Reference</h3> [1]Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022 Jan 27;386(4):316–26. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
POS0158 INCREASED INTIMA-MEDIA THICKNESS OF COMMON FEMORAL VEIN IN BEHÇET’S DISEASE:A SIGN OF FULL LAYER VENOUS WALL INFLAMMATION
Authors: G. Sevik, R. Ergelen, S. Kutluğ Ağaçkiran, H. Direskeneli, F. Alibaz-Oner
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> In vascular involvement of Behçet's disease (BD), inflammatory cells infiltrate mainly the adventitia and media, but only a few inflammatory cells were shown in the intima layer during active arteritis.<sup>[1]</sup> We recently showed that increased common femoral vein (CFV) thickness is a distinctive feature of BD with a specificity higher than 80% for the cut-off value of ≥0.5 mm.<sup>[2]</sup> <h3>Objectives</h3> In this study, we aim to investigate the localization of inflammation in vein wall in BD patients by measuring both whole wall thickness and the intima-media thickness (IMT) of CFV. <h3>Methods</h3> Patients with BD (n=42, 27M/15F) and age- and sex-matched healthy controls (HC) (n=35, 21M/14F) were included in the study. IMT and venous wall thickness of CFV were measured with Doppler ultrasonography. <h3>Results</h3> The mean age was 39.8±10.0 years in BD patients and 36.8±7.9 years in HC. The median disease duration of BD patients was 72 (28.5-162.0) months and 61.9% of them had major organ involvement. The most common major organ involvement was vascular (57.7%) followed by ocular (34.6%), and neurological (7.7%) involvement. Most (66.7%) BD patients were using immunosuppressive treatment. Both IMT-R and IMT-L were significantly higher in BD patients than HC (p&lt;0.0001). The measurements of IMT and venous wall thickness of CFV were shown in Table 1. There was a significant positive correlation between IMT-R and CFV-R, IMT-L and CFV-L measurements (p&lt;0.0001,r=0.918 and p&lt;0.0001, r=0.907, respectively). There was no significant difference between IMT-R and IMT-L measurements in BD patients with and without major organ involvement (p&gt;0.05 for both). <h3>Conclusion</h3> IMT of CFV, as well as CFV wall thickness, is significantly increased in BD patients than HC. Our results suggest that there is a full layer venous wall inflammation including intima-media layer in BD independent of vascular involvement. <h3>References</h3> [1]Kobayashi M, et al. Histopathology, 2000. [2]Alibaz-Oner F., et al. Rheumatology (Oxford), 2021. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
POS0195-PARE PATIENT’S AWARENESS TOWARDS PHYSICAL ACTIVITY IN THE TREATMENT OF AXIAL SPONDYLOARTHRITIS
Authors: D. Kiefer, J. Braun, U. Kiltz, N. Kolle, S. Lucia, I. Andreica, B. Bjoern, P. Sewerin, H. Susanne, X. Baraliakos
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> The course of axSpA is often characterized by impairments in physical function and mobility. Regular physical activity (PA) is a cornerstone of axSpA management. Recent EULAR recommendations for PA have stressed the importance of their implementation [1]. <h3>Objectives</h3> To investigate the awareness on and individual implementation of PA in axSpA patients. <h3>Methods</h3> Patients with axSpA and impaired physical function (BASFI score ≥2.0) were recruited consecutively. All patients underwent a clinical examination including assessments of disease activity, physical function, mobility and global function and also filled out structured questionnaires on knowledge, awareness and individual attitudes to PA. <h3>Results</h3> Out of a total of 100 patients enrolled, 96 were included in the final analysis. Most respondents (n=82, 85.4%) were aware that PA has significant health benefits for patients with axSpA. Even though less than half of the patients (n=44, 45.8%) were aware that recommendations about PA do exist, 45 patients (46.9%) did already fulfil these in terms of frequency/week. 75 (78.1%) of patients knew that every adult should perform activities that maintain or increase muscular strength and endurance for a minimum of 2 days/week, while a majority 90 (93.8%) agree with this statement only 46 (47.9%) did fulfil these recommendations. The majority of patients (n=61, 67.7%) had been informed about the benefits of PA by their physician, and physiotherapy had often been prescribed (n=61, 63.3%). Many patients (n=51, 53.1%) reported to perform individual exercise programs, and some (n=22, 22.9%) supervised PA (Table 1). <h3>Conclusion</h3> Even though the majority of axSpA patients are not aware of the recent EULAR recommendations for PA, many understand and agree that PA is beneficial for their health status, while about half of them already fulfill them in their daily life. Measurements for dissemination and implementations on PA recommendations as a treatment target in a broad patient population need to be developed in order to serve the EULAR recommendations for PA. Part of this work was supported by an unrestricted grant by Novartis Pharma GmbH. <h3>Reference</h3> [1]Rausch Osthoff AK, Niedermann K, Braun J et al. 2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis. Ann Rheum Dis 2018; 77: 1251-1260. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.
Helen Salisbury: Retention, not just training, is key
Authors: Helen Salisbury
Journal: BMJ (2023)

Achieving a place at medical school is the ambition of many school leavers.Competition is intense, and a lot of young people who could become excellent doctors don't have the opportunity to train.It would be to their benefit, and that of the wider public, if the much trailed expansion of medical school places actually came to fruition, 1 but details remain uncertain.The long awaited NHS workforce plan, which might give clarity, is coming "soon," say government sources.
POS0072-HPR EXERCISES TRAINING AS A TREATMENT FOR RHEUMATOID CACHEXIA IN RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: M. Karapinar, A. Karaİbrahİmoğlu, F. Baskurt, Z. Baskurt
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Rheumatoid arthritis (RA) is a systemic inflammatory autoimmune disease that characterized by chronic, symmetric and erosive synovitis that may lead to severe disability and impairments. RA patients frequently have adverse changes in their body composition, with a decrease in muscle mass and an increase in fat mass, a syndrome that is termed rheumatoid cachexia (RC). RC is associated with chronic inflammation, impaired muscle mass and strength and body mass loss, all of which are classical targets of exercise training. <h3>Objectives</h3> This systematic review and meta-analysis aimed to determine the effects of exercise training on body composition included fat mass, lean body mass and muscle strength in patients with rheumatoid arthritis. <h3>Methods</h3> We searched PubMed/Medline, Web of Science, EMBASE, CINHAL, Scopus, Cochrane Library, Google Scholar and Science Direct for relevant articles until November 2022. Systematic review included randomised controlled trials and controlled trials. Pre- and post- exercises intervention data on our primary outcomes included body composition [e.g., using BMI, bioelectrical impedance analysis, fat-free mass index (FFMI)] and isometric knee muscle strength. Two authors independently screened records and data were extracted using Microsoft Excel and exported to STATA version 15.0 software for analysis. Risk of bias was assessed and a random-effects model was used to pool effect sizes by standardized mean differences (SMD). <h3>Results</h3> Six studies with a total of 119 patients with RA in the meta-analysis. Exercises interventions had a median (range) duration of 14 (12-24) weeks and including progressive resistance training, high-intensity resistance training, proprioceptive exercises and water-based exercises programs. Exercises interventions a superior effect compare to control on both fat mass [SDM -0.20 (%95 CI – 1.20, 0.79), p&lt;0.001, i<sup>2</sup>; %91], lean body mass [SDM 0.66 (%95 CI -0.77, 2.09), p&lt; 0.001, i<sup>2</sup>; %95] and isometric knee extensor muscle strength [SDM 3.01 (0.59, 5.43), p&lt;0.001, i<sup>2</sup>; %97] (Figure 1). <h3>Conclusion</h3> Our meta-analysis indicates different exercises trainings effectively decreased fat mass and increased isometric extensor muscle strength and lean mass in patients with RA thereby slowing or reversing RC. <h3>Reference</h3> [1]Roubenoff, R. (2009). Rheumatoid cachexia: a complication of rheumatoid arthritis moves into the 21st century. <i>Arthritis research &amp; therapy</i>, <i>11</i>(2), 1-2. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> None Declared.